333 related articles for article (PubMed ID: 36518162)
1. Reporter gene systems: A powerful tool for
Boy RL; Hong A; Aoki JI; Floeter-Winter LM; Laranjeira-Silva MF
Curr Res Microb Sci; 2022; 3():100165. PubMed ID: 36518162
[TBL] [Abstract][Full Text] [Related]
2. Rapid, Selection-Free, High-Efficiency Genome Editing in Protozoan Parasites Using CRISPR-Cas9 Ribonucleoproteins.
Soares Medeiros LC; South L; Peng D; Bustamante JM; Wang W; Bunkofske M; Perumal N; Sanchez-Valdez F; Tarleton RL
mBio; 2017 Nov; 8(6):. PubMed ID: 29114029
[TBL] [Abstract][Full Text] [Related]
3. One Health Approach to Leishmaniases: Understanding the Disease Dynamics through Diagnostic Tools.
Hong A; Zampieri RA; Shaw JJ; Floeter-Winter LM; Laranjeira-Silva MF
Pathogens; 2020 Oct; 9(10):. PubMed ID: 33019713
[TBL] [Abstract][Full Text] [Related]
4. A Conditional Protein Degradation System To Study Essential Gene Function in Cryptosporidium parvum.
Choudhary HH; Nava MG; Gartlan BE; Rose S; Vinayak S
mBio; 2020 Aug; 11(4):. PubMed ID: 32843543
[No Abstract] [Full Text] [Related]
5. Improvement of the green fluorescent protein reporter system in Leishmania spp. for the in vitro and in vivo screening of antileishmanial drugs.
Pulido SA; Muñoz DL; Restrepo AM; Mesa CV; Alzate JF; Vélez ID; Robledo SM
Acta Trop; 2012 Apr; 122(1):36-45. PubMed ID: 22155571
[TBL] [Abstract][Full Text] [Related]
6. A new chimeric triple reporter fusion protein as a tool for in vitro and in vivo multimodal imaging to monitor the development of African trypanosomes and Leishmania parasites.
Calvo-Alvarez E; Cren-Travaillé C; Crouzols A; Rotureau B
Infect Genet Evol; 2018 Sep; 63():391-403. PubMed ID: 29339220
[TBL] [Abstract][Full Text] [Related]
7. Antiparasitic chemotherapy: tinkering with the purine salvage pathway.
Datta AK; Datta R; Sen B
Adv Exp Med Biol; 2008; 625():116-32. PubMed ID: 18365663
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasites.
Varela-M RE; Villa-Pulgarin JA; Yepes E; Müller I; Modolell M; Muñoz DL; Robledo SM; Muskus CE; López-Abán J; Muro A; Vélez ID; Mollinedo F
PLoS Negl Trop Dis; 2012; 6(4):e1612. PubMed ID: 22506086
[TBL] [Abstract][Full Text] [Related]
9. An in silico functional annotation and screening of potential drug targets derived from Leishmania spp. hypothetical proteins identified by immunoproteomics.
Chávez-Fumagalli MA; Schneider MS; Lage DP; Machado-de-Ávila RA; Coelho EA
Exp Parasitol; 2017 May; 176():66-74. PubMed ID: 28327439
[TBL] [Abstract][Full Text] [Related]
10. Network-Based Approaches Reveal Potential Therapeutic Targets for Host-Directed Antileishmanial Therapy Driving Drug Repurposing.
Martinez-Hernandez JE; Hammoud Z; de Sousa AM; Kramer F; Monte-Neto RLD; Maracaja-Coutinho V; Martin AJM
Microbiol Spectr; 2021 Oct; 9(2):e0101821. PubMed ID: 34668739
[No Abstract] [Full Text] [Related]
11. Vaccines in leishmaniasis: advances in the last five years.
Brodskyn C; de Oliveira CI; Barral A; Barral-Netto M
Expert Rev Vaccines; 2003 Oct; 2(5):705-17. PubMed ID: 14711330
[TBL] [Abstract][Full Text] [Related]
12. Lipid and fatty acid metabolism in trypanosomatids.
Parreira de Aquino G; Mendes Gomes MA; Köpke Salinas R; Laranjeira-Silva MF
Microb Cell; 2021 Nov; 8(11):262-275. PubMed ID: 34782859
[TBL] [Abstract][Full Text] [Related]
13. Challenges and Tools for In Vitro
Cohen A; Azas N
Pathogens; 2021 Dec; 10(12):. PubMed ID: 34959563
[TBL] [Abstract][Full Text] [Related]
14. A non-commercial approach for the generation of transgenic Leishmania tarentolae and its application in antileishmanial drug discovery.
Pineda T; Valencia Y; Flórez MF; Pulido SA; Vélez ID; Robledo SM
Parasitology; 2016 Aug; 143(9):1133-42. PubMed ID: 27174193
[TBL] [Abstract][Full Text] [Related]
15. Recombinant DNA-derived leishmania proteins: from the laboratory to the field.
Kubar J; Fragaki K
Lancet Infect Dis; 2005 Feb; 5(2):107-14. PubMed ID: 15680780
[TBL] [Abstract][Full Text] [Related]
16. Stage-Specific Class I Nucleases of
Freitas-Mesquita AL; Meyer-Fernandes JR
Front Cell Infect Microbiol; 2021; 11():769933. PubMed ID: 34722348
[TBL] [Abstract][Full Text] [Related]
17. Virulence factors of Leishmania parasite: Their paramount importance in unraveling novel vaccine candidates and therapeutic targets.
Kumari D; Mahajan S; Kour P; Singh K
Life Sci; 2022 Oct; 306():120829. PubMed ID: 35872004
[TBL] [Abstract][Full Text] [Related]
18. Protease inhibitors in potential drug development for Leishmaniasis.
Das P; Alam MN; Paik D; Karmakar K; De T; Chakraborti T
Indian J Biochem Biophys; 2013 Oct; 50(5):363-76. PubMed ID: 24772958
[TBL] [Abstract][Full Text] [Related]
19. Cell Cycle, Telomeres, and Telomerase in
Assis LHC; Andrade-Silva D; Shiburah ME; de Oliveira BCD; Paiva SC; Abuchery BE; Ferri YG; Fontes VS; de Oliveira LS; da Silva MS; Cano MIN
Cells; 2021 Nov; 10(11):. PubMed ID: 34831418
[TBL] [Abstract][Full Text] [Related]
20. The role of heparan sulfate in host macrophage infection by
Maciej-Hulme ML; Skidmore MA; Price HP
Biochem Soc Trans; 2018 Aug; 46(4):789-796. PubMed ID: 29934302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
